Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Read more on:    Doxil | Cancer | Sun Pharma
Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug .

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

For FIIs, India is the best in EM basket

Foreign investors are betting top dollar on the country as growth is likely to recover at a time when other emerging markets are battling ...

Markets to remain closed on account of Good Friday

It's a truncated week for Indian stock market with two public holidays this week

India Inc's m-cap nears record

Just 3% lower than the all-time peak seen in Nov 2010; IT and consumption-oriented firms move up the list, with bigger rewards for those ...

Coal India awaiting more triggers

Analysts expect it to raise prices this quarter to offset rising costs; faster clearances seen for project plans but output rise still seen as a ...

FIIs bullish on ICICI Bank; stake hits 6-year high

During quarter ended March, the stock gains 13.3% compared with the Bankex's 12% rise

Back to Top